ArticleBMC musculoskeletal disorders2026
miR-192-5p targets USP1 to regulate osteogenic differentiation and diagnose the occurrence of osteoporotic fracture.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoporosis (OP) in the elderly reduces bone strength, significantly increasing the risk of osteoporotic fracture (OPF). Early screening is essential to alleviate this widespread health problem, and miR-192-5p has recently been identified as a potential candidate. PURPOSE: To elucidate the diagnostic role of miR-192-5p in OPF patients and explore its underlying molecular mechanisms.
methodsmiR-192-5p expression in serum of OPF patients and hBMSCs was determined by real-time quantitative polymerase chain reaction (RT-qPCR). The mRNA levels of osteogenic markers in hBMSCs were also quantified by RT-qPCR. The regulation of hBMSCs by miR-192-5p was determined through methyl thiazolyl tetrazolium (MTT) assay and flow cytometry. The downstream targets of miR-192-5p were validated through luciferase activity assay. The diagnostic potential of miR-192-5p for OPF was evaluated by receiver operating characteristic (ROC) method.
resultsmiR-192-5p level was reduced in OPF patients, and its AUC for distinguishing OPF patients is 0.882. The levels of miR-192-5p and osteogenic markers runt-related transcription factor 2 (RUNX2), osteocalcin (OCN), osteopontin (OPN) and alkaline phosphatase (ALP) were upregulated after induction of differentiation in hBMSCs. Mechanically, inhibition of miR-192-5p may attenuate the upregulation of osteogenic markers and reduce the proliferation of hBMSCs by regulating ubiquitin specific peptidase 1 (USP1).
conclusionmiR-192-5p may serve as a potential biomarker for the diagnosis of OPF, and the miR-192-5p/USP1 axis offers a promising therapeutic target for OPF intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.